Harmony Biosciences Holdings (HRMY) - Net Assets
Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) has net assets worth $910.35 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.27 Billion) and total liabilities ($361.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Harmony Biosciences Holdings to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $910.35 Million |
| % of Total Assets | 71.58% |
| Annual Growth Rate | 40.25% |
| 5-Year Change | 366.59% |
| 10-Year Change | N/A |
| Growth Volatility | 73.43 |
Harmony Biosciences Holdings - Net Assets Trend (2018–2025)
This chart illustrates how Harmony Biosciences Holdings's net assets have evolved over time, based on quarterly financial data. See Harmony Biosciences Holdings (HRMY) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Harmony Biosciences Holdings (2018–2025)
The table below shows the annual net assets of Harmony Biosciences Holdings from 2018 to 2025. For live valuation and market cap data, see HRMY company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $870.22 Million | +32.02% |
| 2024-12-31 | $659.15 Million | +41.15% |
| 2023-12-31 | $466.99 Million | +15.93% |
| 2022-12-31 | $402.84 Million | +115.99% |
| 2021-12-31 | $186.51 Million | +91.92% |
| 2020-12-31 | $97.18 Million | +938.84% |
| 2019-12-31 | $-11.59 Million | -114.21% |
| 2018-12-31 | $81.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Harmony Biosciences Holdings's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 40357600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $160.90 Million | 18.49% |
| Common Stock | $1.00K | 0.00% |
| Other Comprehensive Income | $346.00K | 0.04% |
| Other Components | $708.97 Million | 81.47% |
| Total Equity | $870.22 Million | 100.00% |
Harmony Biosciences Holdings Competitors by Market Cap
The table below lists competitors of Harmony Biosciences Holdings ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Telecom Argentina S.A
F:TEO
|
$1.87 Billion |
|
Vietnam National Petroleum Group
VN:PLX
|
$1.87 Billion |
|
Compañía Cervecerías Unidas S.A
F:CVU
|
$1.87 Billion |
|
SIRIUS REAL ESTATE LTD.
F:EYI
|
$1.87 Billion |
|
Proto Labs Inc
NYSE:PRLB
|
$1.86 Billion |
|
Sinofibers Technology Co Ltd
SHE:300777
|
$1.86 Billion |
|
Guodian Nanjing Automation Co Ltd
SHG:600268
|
$1.86 Billion |
|
Jiangsu Guotai International Group Guomao Co Ltd
SHE:002091
|
$1.86 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harmony Biosciences Holdings's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 659,155,000 to 870,218,000, a change of 211,063,000 (32.0%).
- Net income of 158,687,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 280,000.
- Other factors increased equity by 52,096,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $158.69 Million | +18.24% |
| Other Comprehensive Income | $280.00K | +0.03% |
| Other Changes | $52.10 Million | +5.99% |
| Total Change | $- | 32.02% |
Book Value vs Market Value Analysis
This analysis compares Harmony Biosciences Holdings's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.40x to 2.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.66 | $33.77 | x |
| 2019-12-31 | $-0.18 | $33.77 | x |
| 2020-12-31 | $1.68 | $33.77 | x |
| 2021-12-31 | $3.15 | $33.77 | x |
| 2022-12-31 | $6.59 | $33.77 | x |
| 2023-12-31 | $7.74 | $33.77 | x |
| 2024-12-31 | $11.39 | $33.77 | x |
| 2025-12-31 | $14.86 | $33.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harmony Biosciences Holdings utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.24%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.27%
- • Asset Turnover: 0.68x
- • Equity Multiplier: 1.46x
- Recent ROE (18.24%) is above the historical average (5.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -48.94% | 0.00% | 0.00x | 1.10x | $-48.05 Million |
| 2019 | 0.00% | -2535.06% | 0.06x | 0.00x | $-150.82 Million |
| 2020 | -38.02% | -23.13% | 0.37x | 4.39x | $-46.66 Million |
| 2021 | 18.55% | 11.33% | 0.70x | 2.32x | $15.95 Million |
| 2022 | 45.05% | 41.44% | 0.65x | 1.67x | $141.18 Million |
| 2023 | 27.59% | 22.14% | 0.72x | 1.74x | $82.15 Million |
| 2024 | 22.07% | 20.36% | 0.72x | 1.52x | $79.58 Million |
| 2025 | 18.24% | 18.27% | 0.68x | 1.46x | $71.67 Million |
Industry Comparison
This section compares Harmony Biosciences Holdings's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harmony Biosciences Holdings (HRMY) | $910.35 Million | -48.94% | 0.40x | $1.86 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more